Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $40.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE